Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 7
Submit an article Journal homepage
743
Views
17
CrossRef citations to date
0
Altmetric
Author's View

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

Ravi A Madan Laboratory of Tumor Immunology and Biology; National Cancer Institute; Bethesda, MD USA
,
Christopher R. Heery Laboratory of Tumor Immunology and Biology; National Cancer Institute; Bethesda, MD USA
&
James L. Gulley Laboratory of Tumor Immunology and Biology; National Cancer Institute; Bethesda, MD USACorrespondence[email protected]
Pages 1167-1168 | Received 11 Apr 2012, Accepted 02 May 2012, Published online: 01 Oct 2012

Figures & data

Figure 1. Schematic representation of dosing schedule on trial. V, PROSTVAC-V/TRICOM (vaccinia) × 1 dose + sargramostim daily × 4 doses (no ipilimumab); A, PROSTVAC-F/TRICOM (fowlpox) × 1 dose + ipilimumab × 1 dose + sargramostim daily × 4 doses; F, PROSTVAC-F/TRICOM (fowlpox) × 1 dose + sargramostim daily × 4 doses (no ipilimumab).

Figure 1. Schematic representation of dosing schedule on trial. V, PROSTVAC-V/TRICOM (vaccinia) × 1 dose + sargramostim daily × 4 doses (no ipilimumab); A, PROSTVAC-F/TRICOM (fowlpox) × 1 dose + ipilimumab × 1 dose + sargramostim daily × 4 doses; F, PROSTVAC-F/TRICOM (fowlpox) × 1 dose + sargramostim daily × 4 doses (no ipilimumab).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.